Riskpilot← Back to searchSign inGet full accessPro Ox Bio AB
ABActiveOrg 5569657595Önologgatan 1Diagnostic imaging services and medical laboratory activities · NACE 8691Est. 20141 employees
Revenue 2025
SEK 1,3M
-30% vs 2024
EBITDA margin
16.2%
-73% vs 2024
Equity ratio
7.4%
Financial strength
Net profit 2025
SEK 3K
+328% vs 2024
| Revenue | SEK 1,3M | -30% |
| EBITDA | SEK 204K | -73% |
| Net profit | SEK 3K | +328% |
| Total assets | SEK 4,2M | +8% |
| Equity | SEK 313K | +1% |
| Employees | 1 | — |
Legal name
Pro Ox Bio AB
Org number
5569657595
Legal form
Aktiebolag
NACE code
8691 · Diagnostic imaging services and medical laboratory activities
Founded
19 mars 2014
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Aktiebolaget skall bedriva forskning och utvecklingsarbete inom det medicinska området samt bedriva utveckling, produktion och försäljning av immunologiska produkter ävensom bedriva bioanalysverksamhet och konsultverksamhet inom samma område samt därmed förenlig verksamhet.
Address
Önologgatan 1
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 2 525 | 2 786 | 1 862 | 1 715 | 2 196 | 2 355 | 1 808 | 1 263 |
| Staff expenses | — | — | — | — | — | — | −849 | −794 | −735 | −763 |
| EBITDA | 717 | 733 | 1 212 | 1 392 | 810 | 737 | 1 105 | 1 228 | 743 | 204 |
| Depreciation & amort. | −19 | −54 | −54 | −141 | −96 | −96 | −96 | −96 | — | — |
| EBIT | 698 | 679 | 1 158 | 1 251 | 714 | 641 | 1 009 | 1 132 | 743 | 204 |
| Net financials | — | — | −1 | −12 | 1 | −22 | 2 | 4 | 8 | 30 |
| Profit before tax | 538 | 280 | 5 | 5 | 0 | 4 | 6 | 36 | 1 | 4 |
| Tax | −119 | −64 | −3 | −3 | −1 | −2 | −4 | −10 | −2 | −1 |
| Net profit | 419 | 216 | 2 | 2 | −1 | 2 | 1 | 26 | −1 | 3 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1 035 | 952 | 1 421 | 1 787 | 2 613 | 2 298 | 2 458 | 3 584 | 3 908 | 4 205 |
| Equity | 463 | 279 | 281 | 282 | 282 | 283 | 285 | 311 | 310 | 313 |
| Long-term debt | 0 | 0 | 0 | 1 138 | 1 225 | 983 | 2 024 | 2 956 | 3 514 | 3 824 |
| Short-term debt | 412 | 513 | 981 | 206 | 946 | 871 | 149 | 317 | 84 | 68 |
| Total debt | 412 | 513 | 981 | 1 344 | 2 171 | 1 854 | 2 173 | 3 273 | 3 598 | 3 892 |
EBITDA margin
16.2%
This company
15.8%
Market median
+3% vs market
20162025
Equity ratio
7.4%
This company
38.2%
Market median
-81% vs market
20162025
Return on equity
1.0%
This company
18.4%
Market median
-95% vs market
20162025
Net profit margin
0.3%
This company
8.1%
Market median
-96% vs market
20162025
Asset turnover
0.30×
This company
1.12×
Market median
-73% vs market
20162025
Debt / equity
12.44×
This company
0.62×
Market median
-1906% vs market
20162025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-09-01 – 2020-08-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-09-01 – 2019-08-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-09-01 – 2018-08-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-09-01 – 2017-08-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-09-01 – 2016-08-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
SB Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2022 | — | — |
TM Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Pro Ox AB | Company | 100.0% | 100.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Pro Ox AB
Pro Ox Bio AB Board members of Pro Ox Bio AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Samar Basu | Deputy Chief Executive Officer | 0 companies |
| Tiina Maarit Basu | Chief Executive Officer | 0 companies |